Hipec ovarian cancer

Research aim

Aims at improving surgical treatment and quality of life for patients with ovarian cancer by:
– Finding the right patient groups who benefit by HIPEC
– Improving the HIPEC treatment regime
– Improving knowledge of the working mechanisms of HIPEC

About us

We perform clinical and translational research aiming to improve the Hipec treatment for patients with ovarian cancer. Hipec is an acronym for Hypertherm Intraperitoneal Chemotherapy which is used with cisplatinum in Ovarian Cancer treatment. In 2019 we (together with the other gynaecologic oncology centers in the Netherlands) introduced Hipec as an new standard treatment for selected group of ovarian cancer patients in the Netherlands. This after our landmark publication in the New England Journal of Medicine (van Driel et al 2018).
We collaborate closely with the Research group of the Antoni van Leeuwenhoek Center (Dutch Cancer Institute) in Amsterdam (PI; Dr Willemien van Driel and Prof Dr Gabe Sonke). Currently we investigating the place of Hipec in patients treated with a primary debulking in stage III ovarian cancer. (OVHIPEC-2 trial). We currently looking how to improve the dose administration calculation method for Hipec in ovarium cancer (CISCON trial)